Lilly's Competitive Clinical Research Grant
Lilly's Competitive Clinical Research Grant from Eli Lilly and Company funds independent research on lebrikizumab in dermatology, focusing on efficacy in fibrosing skin conditions and post-inflammatory dyspigmentation.
Funder: Eli Lilly and Company
Due Dates (Anticipated): February 2027: Full application deadline for RFP: Efficacy of Lebrikizumab in patients with fibrosing skin conditions (projected) | February 2027: Full application deadline for RFP: How does lebrikizumab impact post-inflammatory dyspigmentation (projected)
Funding Amounts: Study drug and/or financial support for investigator-initiated studies; specific award size and duration vary by proposal and RFP.
Summary: Supports external investigator-initiated research aligned with Lilly’s scientific interests, with a focus on lebrikizumab in dermatology.
Key Information: This is a forecasted grant opportunity; timelines are projected and subject to change.
Description
Lilly's Competitive Clinical Research Grant provides external researchers with the opportunity to obtain study drug and/or financial support for investigator-initiated studies. The program is structured around publicly posted Requests for Proposals (RFPs) that define specific scientific areas of interest, such as the efficacy of lebrikizumab in fibrosing skin conditions and its impact on post-inflammatory dyspigmentation. Proposals are reviewed by Lilly’s global medical and scientific committees, sometimes with external expert input. Approved research is conducted independently by the grantee, who retains responsibility for study design, execution, and regulatory sponsorship, while leveraging Lilly’s resources and expertise.
